India News | Human Trial of COVID-19 Vaccine Begins at PGI Rohtak
Get latest articles and stories on India at LatestLY. Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at Post-Graduate Institute (PGI) of Medical Sciences in Rohtak on Friday.
Rohtak (Haryana) [India], July 17 (ANI): Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at Post-Graduate Institute (PGI) of Medical Sciences in Rohtak on Friday.
Three volunteers were administered Covaxin.
Also Read | EAM S Jaishankar Retaliates After Rahul Gandhi Posts Video to Corner Modi Govt on 'Geopolitical Setbacks'.
"Human trial of corona vaccine (Covaxin) of Bharat Biotech started at PGI Rohtak today. Three subjects were enrolled today. All have tolerated the vaccine very well. There were no negative impact on them," Haryana Health Minister Anil Vij told ANI.
"It will be tested on more people in the coming days," he added.
Bharat Biotech has successfully developed Covaxin, India's first vaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.
According to the Union Health Ministry, India total count of COVID-19 cases is over 10 lakh COVID-19 including, 3,42,473 active cases, 6,35,757 recovered patients and 25,602 deaths. (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)